Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enanta Pharmaceuticals (ENTAResearch Report) and Global Blood Therapeutics (GBTResearch Report).

Enanta Pharmaceuticals (ENTA)

Oppenheimer analyst Jay Olson assigned a Hold rating to Enanta Pharmaceuticals today and set a price target of $62.00. The company’s shares closed last Wednesday at $51.67.

According to, Olson ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.7% and a 36.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Axovant Gene Therapies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enanta Pharmaceuticals with a $57.00 average price target.

See today’s analyst top recommended stocks >>

Global Blood Therapeutics (GBT)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Global Blood Therapeutics. The company’s shares closed last Wednesday at $81.82, close to its 52-week high of $87.55.

According to, Prasad is a 5-star analyst with an average return of 14.4% and a 55.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Global Blood Therapeutics is a Strong Buy with an average price target of $103.27, implying a 33.3% upside from current levels. In a report issued on April 27, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $112.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Source link